Ligand Pharmaceuticals Incorporated acquires Pfenex Inc. (2020)

Deal facts

Buyer: Ligand Pharmaceuticals Incorporated
Target: Pfenex Inc.
Deal value: Not disclosed
Announced: 10 August 2020
Status: Completed
Sector: Healthcare
Country: United States
Consideration: cash, earn-out

Sources

SEC_EDGAR_8K

What we know

Weekly digest

Join Exit Mode Insider

Ten deal briefs a week, founder commentary, and the patterns worth paying attention to.

Join Exit Mode Insider, £12/mo

Deal timeline

1 update

1 Oct 2020CompletedClosed
Ligand Pharmaceuticals Incorporated completes acquisition of Pfenex Inc.
Item 2.01 Completion of Acquisition or Disposition of Assets. On October 1, 2020, Ligand Pharmaceuticals Incorporated, a Delaware corporation (“Ligand”), completed the previously announced acquisition of Pfenex Inc., a Delaware corporation (“Pfenex”), pursuant to the Agreement and Plan of Merger (the “Merger Agreement”), dated as of August 10, 2020, by and among Ligand, Pfenex and Pelican Acquisit
Source

OpinionExit Mode editorial

We see a clear signal in the transaction where Ligand Pharmaceuticals Incorporated acquired Pfenex Inc. to take the target private. Announced on 10 August 2020, this deal moved a US healthcare firm from public markets into private ownership. The structure relies on a mix of cash and an earn-out. This specific combination often reflects a buyer who wants immediate control but needs the seller to prove future performance before releasing the full price. It is a common mechanic when the acquirer sees value that the market currently underestimates but requires validation over time.

For the SME founder reading this, the choice of an earn-out introduces a distinct commercial risk. It shifts the burden of value creation onto the post-close period. If the business does not hit the agreed targets, the final consideration drops. This is not merely a pricing detail; it is a change-of-control covenant that dictates your operational freedom for years. In the healthcare sector, where regulatory timelines and clinical outcomes drive value, tying a portion of the sale to future milestones can be precarious. The buyer assumes the asset, yet the seller remains financially exposed until the earn-out conditions are satisfied.

The going-private nature of this deal also suggests a desire to escape the short-term pressures of public reporting. Ligand likely sought the flexibility to restructure or integrate Pfenex without quarterly scrutiny. While this offers strategic breathing room, it removes the liquidity event that many founders expect. The deal status is now completed, meaning the terms were accepted and the transition executed. This outcome highlights that even in a sector as stable as healthcare, the path to exit often involves trade-offs between immediate cash and future potential.

You must scrutinise the earn-out triggers in your own data room this week. Do not accept vague language regarding performance metrics. Define the specific clinical or commercial milestones that unlock the deferred payment and ensure they are within your team's direct control. If the targets rely on external regulatory approvals or market shifts you cannot influence, the deal value is illusory. Demand clarity on the measurement period and the dispute resolution mechanism before signing.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2020 deals More going private deals More from Ligand Pharmaceuticals Incorporated All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

5 May 2026CompletedHealthcare

Merck to acquire Terns Pharmaceuticals, Inc.

Merck and Terns Pharmaceuticals, Inc. entered the Exit Mode archive.

Buyer: Merck
Target: Terns Pharmaceuticals, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

27 April 2026CompletedHealthcare

BioMarin Pharmaceutical Inc. to acquire Amicus Therapeutics, Inc.

BioMarin Pharmaceutical Inc. and Amicus Therapeutics, Inc. entered the Exit Mode archive.

Buyer: BioMarin Pharmaceutical Inc.
Target: Amicus Therapeutics, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

23 April 2026CompletedHealthcare

Servier to acquire Day One Biopharmaceuticals, Inc.

Servier and Day One Biopharmaceuticals, Inc. entered the Exit Mode archive.

Buyer: Servier
Target: Day One Biopharmaceuticals, Inc.
Deal value: USD 2,500,000,000
Deal type: going private

Read deal Healthcare deals going private deals United States deals

30 March 2026CompletedHealthcare

Aurinia Pharma U.S., Inc. to acquire Kezar Life Sciences, Inc.

Aurinia Pharma U.S., Inc. and Kezar Life Sciences, Inc. entered the Exit Mode archive.

Buyer: Aurinia Pharma U.S., Inc.
Target: Kezar Life Sciences, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

23 March 2026CompletedHealthcare

Abbott to acquire Exact Sciences Corp

Abbott and Exact Sciences Corp entered the Exit Mode archive.

Buyer: Abbott
Target: Exact Sciences Corp
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

Buyer history